STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
STAT
JANUARY 31, 2024
Novo also projected double-digit growth in sales and operating profit for 2024. In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S. Sickle cell disease affects an estimated 100,000 Americans. Continue to STAT+ to read the full story…
Let's personalize your content